Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004056593 | SCV002687817 | uncertain significance | not specified | 2024-11-17 | criteria provided, single submitter | clinical testing | The p.H422Q variant (also known as c.1266C>G), located in coding exon 5 of the PALLD gene, results from a C to G substitution at nucleotide position 1266. The histidine at codon 422 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005025810 | SCV005657694 | uncertain significance | Pancreatic cancer, susceptibility to, 1 | 2024-02-28 | criteria provided, single submitter | clinical testing |